New therapeutic approaches to resistant hypertension

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 296-302

  Schlaich, Markus P ^a   Krum, Henry ^b   Esler, Murray D ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Aldosterone; Baroreflex; Renal nerves; Renin; Resistant hypertension; Sympathetic; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ALISKIREN; ANGIOTENSIN 1 VACCINE; ANGIOTENSIN 2 VACCINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; BOSENTAN; CYTO 006 ANG QB; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; GUANFACINE; LCZ 696; OMAPATRILAT; PLACEBO; PMD 3117; UNCLASSIFIED DRUG; VACCINE; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CATHETER ABLATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; HOT FLUSH; HUMAN; HYPERTENSION; PRESSORECEPTOR REFLEX; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; VACCINATION; VASCULAR ACCESS DEVICE;

ANTIHYPERTENSIVE AGENTS; BAROREFLEX; HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; KIDNEY; PROGNOSIS; RECEPTORS, ENDOTHELIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; TREATMENT FAILURE;

EID: 77956262787     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0119-1     Document Type: Review

References (47)

1. V Perkovic R Huxley Y Wu, et al. 2007 The burden of blood pressure-related disease: a neglected priority for global health Hypertension 50 991 997 10.1161/HYPERTENSIONAHA.107.095497 1:CAS:528:DC%2BD2sXht1yku7nI 17954719
2. I Hajjar TA Kotchen 2003 Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 290 199 206 10.1001/jama.290.2.199 12851274
3. PA Sarafidis GL Bakris 2008 Resistant hypertension: an overview of evaluation and treatment J Am Coll Cardiol 52 1749 1757 10.1016/j.jacc.2008.08. 036 19022154
4. G Mancia G De Backer A Dominiczak, et al. 2007 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 1105 1187 10.1097/HJH.0b013e3281fc975a 1:CAS:528:DC%2BD2sXmtlWnsr0%3D 17563527
5. HR Black WJ Elliott G Grandits, et al. 2003 Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial JAMA 289 2073 2082 10.1001/jama.289.16.2073 1:CAS:528: DC%2BD3sXjtFKhsLg%3D 12709465
6. WC Cushman CE Ford JA Cutler, et al. 2002 Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 4 393 404 10.1111/j.1524-6175.2001.01481.x
7. DA Calhoun D Jones S Textor, et al. 2008 Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 1403 1419 10.1161/HYPERTENSIONAHA.108.189141 1:CAS:528:DC%2BD1cXlvFaitLw%3D 18391085
8. F de Souza E Muxfeldt R Fiszman G Salles 2010 Efficacy of spironolactone therapy in patients with true resistant hypertension Hypertension 55 147 152 10.1161/HYPERTENSIONAHA.109.140988 19858405
9. N Chapman J Dobson S Wilson, et al. 2007 Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 839 845 10.1161/01.HYP.0000259805.18468.8c 1:CAS:528:DC%2BD2sXivVamt78%3D 17309946
10. JM Wood J Maibaum J Rahuel, et al. 2003 Structure-based design of aliskiren, a novel orally effective renin inhibitor Biochem Biophys Res Commun 308 698 705 10.1016/S0006-291X(03)01451-7 1:CAS:528:DC%2BD3sXmsVGkt7k%3D 12927775
11. J Nussberger G Wuerzner C Jensen HR Brunner 2002 Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril Hypertension 39 E1 E8 10.1161/hy0102.102293 1:CAS:528:DC%2BD38XpvVyktA%3D%3D 11799102
12. AH Gradman RE Schmieder RL Lins, et al. 2005 Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 1012 1018 10.1161/01.CIR.0000156466.02908.ED 1:CAS:528:DC%2BD2MXhsFShu70%3D 15723979
13. JE Frampton MP Curran 2007 Aliskiren: a review of its use in the management of hypertension Drugs 67 1767 1792 10.2165/00003495-200767120-00008 1:CAS:528:DC%2BD2sXhtFGgtb7F 17683174
14. G Nguyen F Delarue C Burckle, et al. 2002 Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin J Clin Invest 109 1417 1427 1:CAS:528:DC%2BD38XktlWlu78%3D 12045255
15. HH Parving F Persson JB Lewis, et al. 2008 Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2433 2446 10.1056/NEJMoa0708379 1:CAS:528:DC%2BD1cXmvFKmtLY%3D 18525041
16. SD Solomon E Appelbaum WJ Manning, et al. 2009 Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation 119 530 537 10.1161/CIRCULATIONAHA.108.826214 1:CAS:528: DC%2BD1MXpt1eksA%3D%3D 19153265
17. JJ McMurray B Pitt R Latini, et al. 2008 Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 17 24 10.1161/CIRCHEARTFAILURE.107.740704 1:CAS:528:DC%2BD1cXosFGnsLY%3D 19808266
18. Solomon SD: Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIRE. Presentation No: 3019-10, presented at American College of Cardiology 59th Annual Scientific Sessions. Atlanta, GA; March 14-16, 2010.
19. A Fiebeler J Nussberger E Shagdarsuren, et al. 2005 Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage Circulation 111 3087 3094 10.1161/CIRCULATIONAHA.104.521625 1:CAS:528:DC%2BD2MXkvVCmu7o%3D 15939810
20. MA Weber 2001 Vasopeptidase inhibitors Lancet 358 1525 1532 10.1016/S0140-6736(01)06584-9 1:STN:280:DC%2BD3MnltFOisA%3D%3D 11705582
21. JB Kostis M Packer HR Black, et al. 2004 Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 103 111 10.1016/j.amjhyper.2003.09. 014 1:CAS:528:DC%2BD2cXmvF2gtw%3D%3D 14751650
22. LM Ruilope A Dukat M Böhm, et al. 2010 Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 1255 1266 10.1016/S0140-6736(09)61966-8 1:CAS:528: DC%2BC3cXksFClsbw%3D 20236700 This is the first study to report on the safety and BP-lowering effects of an ARB/neprilysin inhibitor combination
23. MJ Brown J Coltart K Gunewardena, et al. 2004 Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects Clin Sci (Lond) 107 167 173 10.1042/CS20030381 1:CAS:528:DC%2BD2cXlvFGqt7Y%3D
24. PM Ambuhl AC Tissot A Fulurija, et al. 2007 A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity J Hypertens 25 63 72 10.1097/HJH.0b013e32800ff5d6 17143175
25. AC Tissot P Maurer J Nussberger, et al. 2008 Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study Lancet 371 821 827 10.1016/S0140-6736(08)60381-5 1:CAS:528:DC%2BD1cXivFyqtbY%3D 18328929 This study provides evidence of successful immunization against angiotensin II and associated BP-lowering effects
26. H Krum RJ Viskoper Y Lacourciere, et al. 1998 The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators N Engl J Med 338 784 790 10.1056/NEJM199803193381202 1:CAS:528:DyaK1cXitlChtbs%3D 9504938
27. E Raichlin A Prasad V Mathew, et al. 2008 Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis Hypertension 52 522 528 10.1161/HYPERTENSIONAHA.108.113068 1:CAS:528: DC%2BD1cXpvFKgs7w%3D 18695150
28. R Nakov E Pfarr S Eberle 2002 Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension Am J Hypertens 15 7 Pt 1 583 589 10.1016/S0895-7061(02)02933-3 1:CAS:528:DC%2BD38XlvVSktr4%3D 12118903
29. HR Black GL Bakris MA Weber, et al. 2007 Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study J Clin Hypertens (Greenwich) 9 760 769 10.1111/j.1524-6175.2007.07244.x 1:CAS:528:DC%2BD2sXht12rt7%2FE
30. MA Weber H Black G Bakris, et al. 2009 A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial Lancet 374 1423 1431 10.1016/S0140-6736(09)61500-2 1:CAS:528:DC%2BD1MXhtlSru7jK 19748665 This study provides evidence for a potentially important role of endothelin antagonism in resistant hypertension
31. TE Lohmeier ED Irwin MA Rossing, et al. 2004 Prolonged activation of the baroreflex produces sustained hypotension Hypertension 43 306 311 10.1161/01.HYP.0000111837.73693.9b 1:CAS:528:DC%2BD2cXitVajsLw%3D 14707159
32. KA Illig M Levy L Sanchez, et al. 2006 An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial J Vasc Surg 44 1213 1218 10.1016/j.jvs.2006.08.024 17145423
33. EG Lovett J Schafer CL Kaufman 2009 Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies Conf Proc IEEE Eng Med Biol Soc 2009 4626 4630 19963854 This article presents an overview of safety and efficacy data on carotid sinus stimulation in resistant hypertension
34. LA Sanchez K Illig M Levy, et al. 2010 Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology Ann Vasc Surg 24 178 184 10.1016/j.avsg.2009.10.003 20036504
35. K Heusser J Tank S Engeli, et al. 2010 Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients Hypertension 55 619 626 10.1161/HYPERTENSIONAHA.109.140665 1:CAS:528:DC%2BC3cXitVKku7k%3D 20101001
36. KC Young JC Teeters CG Benesch, et al. 2009 Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator J Clin Hypertens (Greenwich) 11 555 563 10.1111/j.1751-7176.2009.00163.x
37. VM Campese 1997 Neurogenic factors and hypertension in chronic renal failure J Nephrol 10 184 187 1:STN:280:DyaK1c%2Fhsleltg%3D%3D 9377724
38. S Ye M Gamburd P Mozayeni, et al. 1998 A limited renal injury may cause a permanent form of neurogenic hypertension Am J Hypertens 11 6 Pt 1 723 728 10.1016/S0895-7061(98)00030-2 1:CAS:528:DyaK1cXktlers78%3D 9657632
39. S Ye H Zhong V Yanamadala VM Campese 2002 Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity Am J Hypertens 15 717 724 10.1016/S0895-7061(02)02959-X 1:CAS:528:DC%2BD38Xms1aisLo%3D 12160195
40. VM Campese 2000 Neurogenic factors and hypertension in renal disease Kidney Int 57 Suppl 75 S2 S6 10.1046/j.1523-1755.2000.07511.x
41. VM Campese E Kogosov 1995 Renal afferent denervation prevents hypertension in rats with chronic renal failure Hypertension 25 4 Pt 2 878 882 1:STN:280:DyaK2M3jvVSjsw%3D%3D 7721447
42. VM Campese E Kogosov M Koss 1995 Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat Am J Kidney Dis 26 861 865 10.1016/0272-6386(95)90456-5 1:STN:280:DyaK28%2FlsV2isA%3D%3D 7485145
43. RH Smithwick JE Thompson 1953 Splanchnicectomy for essential hypertension; results in 1, 266 cases J Am Med Assoc 152 1501 1504 1:STN:280:DyaG3s%2Fos1artg%3D%3D 13061307
44. DM Morrissey VS Brookes WT Cooke 1953 Sympathectomy in the treatment of hypertension; review of 122 cases Lancet 1 6757 403 408 10.1016/S0140-6736(53) 91589-X 1:STN:280:DyaG3s%2FkvVKquw%3D%3D 13024041
45. MP Schlaich PA Sobotka H Krum, et al. 2009 Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept Hypertension 54 1195 1201 10.1161/HYPERTENSIONAHA.109.138610 1:CAS:528:DC%2BD1MXhtl2qurrM 19822798
46. H Krum M Schlaich R Whitbourn, et al. 2009 Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 1275 1281 10.1016/S0140-6736(09) 60566-3 19332353 This study presents the first data on the safety and efficacy of a novel catheter-based approach to functionally denervate the human kidney, demonstrating a favorable safety profile and substantial and sustained reductions in BP
47. MP Schlaich PA Sobotka H Krum, et al. 2009 Renal sympathetic-nerve ablation for uncontrolled hypertension N Engl J Med 361 932 934 10.1056/NEJMc0904179 1:CAS:528:DC%2BD1MXhtVKhtbrL 19710497